Release Date: 28/08/16 01:38 Summary: FY16 4E, Directors Report and Financial Statements-CAB.AX Price Sensitive: Yes Download Document 1.67MB Download
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status